1-7 of 7
Jaffer A. Ajani
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract B126: Co-clinical trial of novel bispecific anti-HER2 antibody Zanidatamab in Patient-Derived Xenografts

Timothy P DiPeri, Kurt W Evans, Bailiang Wang, Ming Zhao, Argun Akcakanat, Maria Gabriela Raso, Yasmeen Q Rizvi, Xiaofeng Zheng, Anil Korkut, Kaushik Varadarajan, Burak Uzunparmak, Ecaterina E Dumbrava, Shubham Pant, Jaffer A Ajani, Paula Pohlmann, V Behrana Jensen, Milind Javle, Jordi Rodon, Funda Meric-Bernstam
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): B126.
https://doi.org/10.1158/1535-7163.TARG-23-B126
Published: 01 December 2023
View article titled, Abstract B126: Co-clinical trial of novel bispecific anti-HER2 antibody Zanidatamab in Patient-Derived Xenografts
Journal Articles

Abstract A085: BI KRASmulti, a first-in-class, orally bioavailable and direct inhibitor of diverse oncogenic KRAS variants drives tumor regression in preclinical models and validates wild-type amplified KRAS as a therapeutic target

Antonio Tedeschi, Lorenz Herdeis, Valeria Santoro, Fabio Savarese, Birgit Wilding, Matthias Treu, Julian Fuchs, Joachim Bröker, Tobias Wunberg, Michael Gmachl, Rumpel Klaus, Fiorella Schischlik, Jesse Lipp, David H. Peng, Mariah Williams, Charles Deckard, Vandhana Ramamoorthy, Joseph R. Daniele, Jaffer A. Ajani, Funda Meric-Bernstam, Christopher P. Vellano, Joseph R. Marszalek, Timothy P. Heffernan, Darryl McConnell, Mark Pearson, Norbert Kraut, Dorothea Rudolph
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): A085.
https://doi.org/10.1158/1535-7163.TARG-23-A085
Published: 01 December 2023
View article titled, Abstract A085: BI KRAS<sup>multi</sup>, a first-in-class, orally bioavailable and direct inhibitor of diverse oncogenic KRAS variants drives tumor regression in preclinical models and validates wild-type amplified KRAS as a therapeutic target
Journal Articles

Discordance of HER2 Expression and/or Amplification on Repeat Testing

Timothy P. DiPeri, Kathleen Kong, Kaushik Varadarajan, Daniel D. Karp, Jaffer A. Ajani, Shubham Pant, Michael F. Press, Sarina A. Piha-Paul, Ecaterina E. Dumbrava, Funda Meric-Bernstam
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (8): 976–984.
https://doi.org/10.1158/1535-7163.MCT-22-0630
Published: 01 August 2023
View article titled, Discordance of HER2 Expression and/or Amplification on Repeat Testing
Open the PDF for Discordance of HER2 Expression and/or Amplification on Repeat Testing in another window
Includes: Supplementary data
Journal Articles

The DNA Endonuclease Mus81 Regulates ZEB1 Expression and Serves as a Target of BET4 Inhibitors in Gastric Cancer

Yuping Yin, Weizhen Liu, Qian Shen, Peng Zhang, Lulu Wang, Ruikang Tao, Hang Li, Xianxiong Ma, Xiangyu Zeng, Jae-Ho Cheong, Shumei Song, Jaffer A. Ajani, Gordon B. Mills, Kaixiong Tao, Guang Peng
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (8): 1439–1450.
https://doi.org/10.1158/1535-7163.MCT-18-0833
Published: 01 August 2019
View article titled, The DNA Endonuclease Mus81 Regulates ZEB1 Expression and Serves as a Target of BET4 Inhibitors in Gastric Cancer
Open the PDF for The DNA Endonuclease Mus81 Regulates ZEB1 Expression and Serves as a Target of BET4 Inhibitors in Gastric Cancer in another window
Includes: Supplementary data
Journal Articles

A Novel YAP1 Inhibitor Targets CSC-Enriched Radiation-Resistant Cells and Exerts Strong Antitumor Activity in Esophageal Adenocarcinoma

Shumei Song, Min Xie, Ailing W. Scott, Jiankang Jin, Lang Ma, Xiaochuan Dong, Heath D. Skinner, Randy L. Johnson, Sheng Ding, Jaffer A. Ajani
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2018) 17 (2): 443–454.
https://doi.org/10.1158/1535-7163.MCT-17-0560
Published: 01 February 2018
View article titled, A Novel YAP1 Inhibitor Targets CSC-Enriched Radiation-Resistant Cells and Exerts Strong Antitumor Activity in Esophageal Adenocarcinoma
Open the PDF for A Novel YAP1 Inhibitor Targets CSC-Enriched Radiation-Resistant Cells and Exerts Strong Antitumor Activity in Esophageal Adenocarcinoma in another window
Includes: Supplementary data
Journal Articles

Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer

Josep Tabernero, Atsushi Ohtsu, Kei Muro, Eric Van Cutsem, Sang Cheul Oh, György Bodoky, Yasuhiro Shimada, Shuichi Hironaka, Jaffer A. Ajani, Jiri Tomasek, Howard Safran, Kumari Chandrawansa, Yanzhi Hsu, Michael Heathman, Azhar Khan, Lan Ni, Allen S. Melemed, Ling Gao, David Ferry, Charles S. Fuchs
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2017) 16 (10): 2215–2222.
https://doi.org/10.1158/1535-7163.MCT-16-0895
Published: 02 October 2017
View article titled, Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer
Open the PDF for Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer in another window
Includes: Supplementary data
Journal Articles

Pretherapy nuclear factor-κB status, chemoradiation resistance, and metastatic progression in esophageal carcinoma

Julie G. Izzo, Arlene M. Correa, Tsung-Teh Wu, Usha Malhotra, Clifford K.S. Chao, Rajyalakshmi Luthra, Joe Ensor, Alexander Dekovich, Zhongxing Liao, Walter N. Hittelman, Bharat B. Aggarwal, Jaffer A. Ajani
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2006) 5 (11): 2844–2850.
https://doi.org/10.1158/1535-7163.MCT-06-0351
Published: 22 November 2006
View article titled, Pretherapy nuclear factor-κB status, chemoradiation resistance, and metastatic progression in esophageal carcinoma
Open the PDF for Pretherapy nuclear factor-κB status, chemoradiation resistance, and metastatic progression in esophageal carcinoma in another window